Cargando…

Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma

BACKGROUD: Cancer stemness is associated with metastases in kidney renal clear cell carcinoma (KIRC) and negatively correlates with immune infiltrates. Recent stemness evaluation methods based on the absolute expression have been proposed to reveal the relationship between stemness and cancer. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Lixing, Zou, Guoying, Cheng, Rui, Wang, Pingping, Ma, Kexin, Cao, Huimin, Zhou, Wenyang, Jin, Xiyun, Xu, Zhaochun, Huang, Yan, Lin, Xiaoyu, Nie, Huan, Jiang, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204412/
https://www.ncbi.nlm.nih.gov/pubmed/34130646
http://dx.doi.org/10.1186/s12885-021-08470-8
_version_ 1783708334828814336
author Xiao, Lixing
Zou, Guoying
Cheng, Rui
Wang, Pingping
Ma, Kexin
Cao, Huimin
Zhou, Wenyang
Jin, Xiyun
Xu, Zhaochun
Huang, Yan
Lin, Xiaoyu
Nie, Huan
Jiang, Qinghua
author_facet Xiao, Lixing
Zou, Guoying
Cheng, Rui
Wang, Pingping
Ma, Kexin
Cao, Huimin
Zhou, Wenyang
Jin, Xiyun
Xu, Zhaochun
Huang, Yan
Lin, Xiaoyu
Nie, Huan
Jiang, Qinghua
author_sort Xiao, Lixing
collection PubMed
description BACKGROUD: Cancer stemness is associated with metastases in kidney renal clear cell carcinoma (KIRC) and negatively correlates with immune infiltrates. Recent stemness evaluation methods based on the absolute expression have been proposed to reveal the relationship between stemness and cancer. However, we found that existing methods do not perform well in assessing the stemness of KIRC patients, and they overlooked the impact of alternative splicing. Alternative splicing not only progresses during the differentiation of stem cells, but also changes during the acquisition of the stemness features of cancer stem cells. There is an urgent need for a new method to predict KIRC-specific stemness more accurately, so as to provide help in selecting treatment options. METHODS: The corresponding RNA-Seq data were obtained from the The Cancer Genome Atlas (TCGA) data portal. We also downloaded stem cell RNA sequence data from the Progenitor Cell Biology Consortium (PCBC) Synapse Portal. Independent validation sets with large sample size and common clinic pathological characteristics were obtained from the Gene Expression Omnibus (GEO) database. we constructed a KIRC-specific stemness prediction model using an algorithm called one-class logistic regression based on the expression and alternative splicing data to predict stemness indices of KIRC patients, and the model was externally validated. We identify stemness-associated alternative splicing events (SASEs) by analyzing different alternative splicing event between high- and low- stemness groups. Univariate Cox and multivariable logistic regression analysisw as carried out to detect the prognosis-related SASEs respectively. The area under curve (AUC) of receiver operating characteristic (ROC) was performed to evaluate the predictive values of our model. RESULTS: Here, we constructed a KIRC-specific stemness prediction model with an AUC of 0.968,and to provide a user-friendly interface of our model for KIRC stemness analysis, we have developed KIRC Stemness Calculator and Visualization (KSCV), hosted on the Shiny server, can most easily be accessed via web browser and the url https://jiang-lab.shinyapps.io/kscv/. When applied to 605 KIRC patients, our stemness indices had a higher correlation with the gender, smoking history and metastasis of the patients than the previous stemness indices, and revealed intratumor heterogeneity at the stemness level. We identified 77 novel SASEs by dividing patients into high- and low- stemness groups with significantly different outcome and they had significant correlations with expression of 17 experimentally validated splicing factors. Both univariate and multivariate survival analysis demonstrated that SASEs closely correlated with the overall survival of patients. CONCLUSIONS: Basing on the stemness indices, we found that not only immune infiltration but also alternative splicing events showed significant different at the stemness level. More importantly, we highlight the critical role of these differential alternative splicing events in poor prognosis, and we believe in the potential for their further translation into targets for immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08470-8.
format Online
Article
Text
id pubmed-8204412
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82044122021-06-16 Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma Xiao, Lixing Zou, Guoying Cheng, Rui Wang, Pingping Ma, Kexin Cao, Huimin Zhou, Wenyang Jin, Xiyun Xu, Zhaochun Huang, Yan Lin, Xiaoyu Nie, Huan Jiang, Qinghua BMC Cancer Research BACKGROUD: Cancer stemness is associated with metastases in kidney renal clear cell carcinoma (KIRC) and negatively correlates with immune infiltrates. Recent stemness evaluation methods based on the absolute expression have been proposed to reveal the relationship between stemness and cancer. However, we found that existing methods do not perform well in assessing the stemness of KIRC patients, and they overlooked the impact of alternative splicing. Alternative splicing not only progresses during the differentiation of stem cells, but also changes during the acquisition of the stemness features of cancer stem cells. There is an urgent need for a new method to predict KIRC-specific stemness more accurately, so as to provide help in selecting treatment options. METHODS: The corresponding RNA-Seq data were obtained from the The Cancer Genome Atlas (TCGA) data portal. We also downloaded stem cell RNA sequence data from the Progenitor Cell Biology Consortium (PCBC) Synapse Portal. Independent validation sets with large sample size and common clinic pathological characteristics were obtained from the Gene Expression Omnibus (GEO) database. we constructed a KIRC-specific stemness prediction model using an algorithm called one-class logistic regression based on the expression and alternative splicing data to predict stemness indices of KIRC patients, and the model was externally validated. We identify stemness-associated alternative splicing events (SASEs) by analyzing different alternative splicing event between high- and low- stemness groups. Univariate Cox and multivariable logistic regression analysisw as carried out to detect the prognosis-related SASEs respectively. The area under curve (AUC) of receiver operating characteristic (ROC) was performed to evaluate the predictive values of our model. RESULTS: Here, we constructed a KIRC-specific stemness prediction model with an AUC of 0.968,and to provide a user-friendly interface of our model for KIRC stemness analysis, we have developed KIRC Stemness Calculator and Visualization (KSCV), hosted on the Shiny server, can most easily be accessed via web browser and the url https://jiang-lab.shinyapps.io/kscv/. When applied to 605 KIRC patients, our stemness indices had a higher correlation with the gender, smoking history and metastasis of the patients than the previous stemness indices, and revealed intratumor heterogeneity at the stemness level. We identified 77 novel SASEs by dividing patients into high- and low- stemness groups with significantly different outcome and they had significant correlations with expression of 17 experimentally validated splicing factors. Both univariate and multivariate survival analysis demonstrated that SASEs closely correlated with the overall survival of patients. CONCLUSIONS: Basing on the stemness indices, we found that not only immune infiltration but also alternative splicing events showed significant different at the stemness level. More importantly, we highlight the critical role of these differential alternative splicing events in poor prognosis, and we believe in the potential for their further translation into targets for immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08470-8. BioMed Central 2021-06-15 /pmc/articles/PMC8204412/ /pubmed/34130646 http://dx.doi.org/10.1186/s12885-021-08470-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xiao, Lixing
Zou, Guoying
Cheng, Rui
Wang, Pingping
Ma, Kexin
Cao, Huimin
Zhou, Wenyang
Jin, Xiyun
Xu, Zhaochun
Huang, Yan
Lin, Xiaoyu
Nie, Huan
Jiang, Qinghua
Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
title Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
title_full Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
title_fullStr Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
title_full_unstemmed Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
title_short Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
title_sort alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204412/
https://www.ncbi.nlm.nih.gov/pubmed/34130646
http://dx.doi.org/10.1186/s12885-021-08470-8
work_keys_str_mv AT xiaolixing alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT zouguoying alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT chengrui alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT wangpingping alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT makexin alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT caohuimin alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT zhouwenyang alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT jinxiyun alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT xuzhaochun alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT huangyan alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT linxiaoyu alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT niehuan alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma
AT jiangqinghua alternativesplicingassociatedwithcancerstemnessinkidneyrenalclearcellcarcinoma